A Multi-centre, Open Label, Observational, Non-interventional, Post Marketing Surveillance to Evaluate Safety and Effectiveness During Long-term Treatment With Tresiba (Insulin Degludec) in Patients With Diabetes Mellitus Requiring Insulin Therapy Under Normal Clinical Practice Conditions
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 14 Aug 2018
At a glance
- Drugs Insulin degludec (Primary)
- Indications Diabetes mellitus; Type 1 diabetes mellitus; Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Novo Nordisk
- 03 Aug 2018 Planned End Date changed from 1 Apr 2019 to 30 Apr 2019.
- 03 Aug 2018 Planned primary completion date changed from 1 Apr 2019 to 30 Apr 2019.
- 11 May 2016 Status changed from recruiting to active, no longer recruiting.